EGFR and non-small cell lung carcinoma: Postoperative use of osimertinib for 3 years with or without adjuvant chemotherapy, as evidenced by the pivotal ADAURA trial in patients with resected stage IB-IIIA NSCLC who have EGFR exon 19 deletions or exon 21 L858R mutationshas significantly extended both DFS (90% vs. 44% at 2 years, 73% vs. 38% at 4 years) with HR of 0.17 at 2 years and 0.23 at 4 years as well as OS and furthermore CNS disease free rate was also significantly improved- 92% vs. 81% compared to placebo [19, 20].